{"transactions":[{"id":1761836,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-11T10:02:08.000Z","date":"2023-10-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 6)"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 6) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 6)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 6) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."}],"balance_after":0,"derivative":{"exercise_price":2.7,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-23-047729","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000114036123047729/form4.xml","form_type":"4"}},{"id":1761835,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-10-11T10:02:08.000Z","date":"2023-10-10","kind":"other","planned":false,"acquired":false,"shares":278333,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This line item represents unvested RSAs held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This line item represents unvested RSAs held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-047729","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000114036123047729/form4.xml","form_type":"4"}},{"id":1761834,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-10-11T10:02:08.000Z","date":"2023-10-10","kind":"grant","planned":false,"acquired":true,"shares":85000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This line item represents unvested restricted stock awards (\"RSAs\") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This line item represents unvested restricted stock awards (\"RSAs\") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest."}],"balance_after":278333,"source":{"system":"sec-edgar","filing":"0001140361-23-047729","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000114036123047729/form4.xml","form_type":"4"}},{"id":1761833,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-10-11T10:02:08.000Z","date":"2023-10-10","kind":"other","planned":false,"acquired":false,"shares":33685,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation (\"Parent\") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub completed a tender offer (the \"Offer\") for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the \"Effective Time\" with the Issuer surviving the merger). (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the \"Cash Amount\") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a \"CVR\") per Share (the \"CVR Amount\" and together with the Cash Amount, the \"Merger Consideration\"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a \"Milestone Payment\")."}],"balance_after":193333,"source":{"system":"sec-edgar","filing":"0001140361-23-047729","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000114036123047729/form4.xml","form_type":"4"}},{"id":2007819,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-02-17T16:21:00.000Z","date":"2023-02-15","kind":"sale","acquired":false,"shares":3173,"price":0.5418,"value":1719.1314,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":227018,"source":{"system":"sec-edgar","filing":"0001062993-23-004049","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000106299323004049/form4.xml","form_type":"4"}},{"id":2024853,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-02-09T17:09:41.000Z","date":"2023-02-08","kind":"tax_withholding","acquired":false,"shares":5463,"price":0.5965,"value":3258.6795,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":230191,"source":{"system":"sec-edgar","filing":"0000899243-23-004441","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000089924323004441/doc4.xml","form_type":"4"}},{"id":2024852,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-02-09T17:09:41.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":18864,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock award was granted in lieu of a portion of a cash bonus earned by the Reporting Person and fully vested as of the grant date."}],"balance_after":235654,"source":{"system":"sec-edgar","filing":"0000899243-23-004441","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000089924323004441/doc4.xml","form_type":"4"}},{"id":2036291,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-02-02T20:12:37.000Z","date":"2023-02-01","kind":"tax_withholding","acquired":false,"shares":5841,"price":0.5952,"value":3476.5632,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":216790,"source":{"system":"sec-edgar","filing":"0000899243-23-003730","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000089924323003730/doc4.xml","form_type":"4"}},{"id":2036290,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-02-02T20:12:37.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":17631,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock award was granted in lieu of a portion of a cash bonus earned by the Reporting Person and fully vested as of the grant date."}],"balance_after":222631,"source":{"system":"sec-edgar","filing":"0000899243-23-003730","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000089924323003730/doc4.xml","form_type":"4"}},{"id":2046449,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-01-25T17:30:17.000Z","date":"2023-01-24","kind":"grant","acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award will fully vest in two installments, subject to continued employment with the Company through the applicable vesting date: 1/3 of the restricted stock will vest on February 1, 2024; and 2/3 of the restricted stock will vest on February 1, 2025."}],"balance_after":205000,"source":{"system":"sec-edgar","filing":"0001062993-23-001388","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000106299323001388/form4.xml","form_type":"4"}},{"id":2394659,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-15T16:13:31.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date."}],"balance_after":200000,"derivative":{"exercise_price":2.7,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001062993-22-004450","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000106299322004450/form4.xml","form_type":"4"}},{"id":2394658,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-02-15T16:13:31.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests in 3 equal annual installments on the first, second, and third anniversaries of the date of grant, beginning on February 14, 2023."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001062993-22-004450","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000106299322004450/form4.xml","form_type":"4"}},{"id":2944593,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2020-12-15T06:20:11.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":5586,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share."}],"balance_after":10586,"source":{"system":"sec-edgar","filing":"0001493152-20-023590","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000149315220023590/ownership.xml","form_type":"4"}},{"id":3067687,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, no par value","published_at":"2020-08-05T19:36:37.000Z","date":"2020-08-03","kind":"purchase","acquired":true,"shares":5000,"price":1.3296,"value":6648.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001493152-20-014772","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000149315220014772/ownership.xml","form_type":"4"}},{"id":3277250,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase common stock","published_at":"2020-02-12T21:53:35.000Z","date":"2020-02-10","kind":"grant","acquired":true,"shares":204000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on February 10, 2020 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date."}],"balance_after":204000,"derivative":{"exercise_price":2.63,"expiration_date":"2030-02-09","underlying":"Common Stock","underlying_shares":204000},"source":{"system":"sec-edgar","filing":"0001493152-20-002154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000149315220002154/ownership.xml","form_type":"4"}},{"id":3590814,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":109066,"kind":"person","name":"Parker Albert P","position":1,"cik":"0001750079","reported_name":"Parker Albert P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2019-03-18T19:53:43.000Z","date":"2019-03-14","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on March 14, 2019 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date."}],"balance_after":200000,"derivative":{"exercise_price":3.52,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-19-020133","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750079/000120919119020133/doc4.xml","form_type":"4"}}]}